Our Focus
We focus on the areas that others shy away from; pioneering treatments for hard to treat, often neglected cancers.
Our commitment is unwavering: tackling the most challenging cancers that others overlook. We specialise in pioneering treatments for hard to treat, often neglected cancers, dedicating our resources and expertise to these critical areas. Our mission is driven by the belief that every patient deserves innovative, effective care — regardless of their diagnosis.
By focusing on cancers with high unmet need, we aim to make a profound impact on patient outcomes, offering hope and new possibilities where few exist. Our dedication to addressing these critical gaps in cancer care underscores our commitment to transforming the landscape of oncology and delivering tangible benefits to those who need it most.
Changing Lives
More time
for the moments that matter
We are setting new standards for treatment efficacy and safety, whilst significantly reducing negative side effects. As a leader in producing oral small molecules, our medicines can be taken independently at home, minimising disruption to day-to-day living.
Improving clinical profiles and extending quality of life, we enable patients to spend more quality time with the people that matter most to them.
“The impact of roginolisib on my life has been immeasurable. Not only am I still here, but I’m still able to enjoy all of the things I love doing, like being active with my friends and family.”
– Clinical trial patient, Europe
“Patients tolerated roginolisib very well and allowed the drug to be given for several months resulting in longer than historically expected overall survival.”
– Professor Michele Maio, Università Degli Studi Di Siena
“I have been very impressed with the safety profile of roginolisib and patients taking this drug have been able to live longer than expected.”
– Professor Dr Armando Santoro, Humanitas Milan
Clinical Trials
Interested in participating in groundbreaking research? Here you can find out more about our trials and how you may be able to play your part in the advancement of patient-first oncology.
Uveal melanoma is a rare cancer arising within the uveal tract of the eye. When the cancer metastasizes, which it does in approximately 50% of patients, there are limited treatment options and projected overall survival is only a year.
PI3Kδ over-expression stimulates multiple cancer mechanisms and has an oncogenic role in many tumor types, including uveal melanoma. Allosteric modulation of PI3Kδ by roginolisib boosts antitumor immunity by directly modulating regulatory and cytotoxic T-cells, reducing immunosuppression and also inhibits cancer cell survival directly. Compelling data from the ongoing Phase I/II DIONE-01 study has supported the rational to expand the clinical program to a randomized controlled Phase II trial which will start later in 2024.
Further details will be announced soon.
IOA-244-101 STUDY NCT04328844 (DIONE-01)
IOA-244-101 is an open label, dose escalation and expansion multicentre study of roginolisib in patients with solid tumors and hematological malignancies. The completed dose-escalation phase (Part A) evaluated the safety and tolerability of roginolisib as monotherapy and documented preliminary signs of clinical efficacy benefit.
The ongoing dose-expansion phase (Part B) is evaluating the safety, tolerability and clinical activity of roginolisib as monotherapy at the biological effective dose in uveal melanoma. As the trial matures roginolisib continues to be well tolerated at the recommended Phase 2 dose of 80mg for long periods of time, and demonstrates prolonged clinical activity in some patients.
Additional study information can be found by visiting:
Pancreatic cancer is one of the most lethal cancers and is associated with devastating impact on the quality of life of patients. Current treatments are largely ineffective and there is a need for game-changing therapies. Inhibition of autotaxin is a novel treatment strategy that offers a three-pronged attack on the tumor through direct cancer cell inhibition, immune effector stimulation and inhibition of fibrotic processes, giving drugs and immune cells better access to the tumor.
Translational research showing the potential of cambritaxestat in multiple cancer models, including pancreatic cancer, has recently been published in the ESMO journal Immuno-Oncology and Technology (IOTECH), Cancer Research, the Journal of Experimental & Clinical Cancer Research, and Cancers. Across these publications, cambritaxestat showed strong reduction of metastasis and tumor outgrowth in preclinical models, as well as safe and tolerable dosing in healthy volunteers.
Cambritaxestat is currently being investigated in the ongoing Phase I AION-02 study.
IOA-289-102 STUDY NCT05586516 (AION-02)
The IOA-289-102 Phase 1 study is investigating the safety, tolerability and activity of cambritaxestat in combination with standard chemotherapy at escalating doses in approximately 24 patients with metastatic pancreatic cancer.
Additional study information can be found by visiting:
Trial in planning will investigate dostarlimab + roginolisib +/- docetaxel in patients with NSCLC resistant to first-line checkpoint inhibitor therapy.
Further details will be announced soon.
Trial in planning; further details to be announced soon.
Trial in planning; further details to be announced soon.
Trial in planning; further details to be announced soon.
Useful Resources
Battling cancer or supporting somebody who is, can make you feel like you have a million questions and no answers. Below are some resources that may help.
Not sure where to turn?
Get support.
